Organon & Co's VTAMA Cream Receives Strong Dermatology Recommendation

Organon & Co. (NYSE:OGN) saw a surge in stock price after announcing its VTAMA cream received a strong recommendation for managing atopic dermatitis. The cream is steroid-free, with no restrictions on use duration or body surface area affected, making it an effective and safe option for patients.

Organon & Co. (NYSE:OGN) is a global pharmaceutical company specializing in women’s health, established brands, and biosimilars. While OGN shows potential, other AI stocks may offer greater upside potential with less downside risk. Investors seeking undervalued AI stocks can explore further in a free report.

For more investment opportunities, check out articles on stocks that are predicted to double in three years or hidden AI stocks to buy now. This news is originally published on Insider Monkey. Organon & Co. (NYSE:OGN) continues to innovate in the healthcare industry with its effective therapies and solutions.

Read more at Yahoo Finance: Organon & Co. (OGN) Announces American Academy of Dermatology’s Strong Recommendation for VTAMA Cream